Targeting neural-restrictive silencer factor sensitizes tumor cells to antibody-based cancer immunotherapy in vitro via multiple mechanisms

Journal of Immunology

Volumn 184, Issue 11, 2010, Pages 6035-6042

  Kolev, Martin V ^a   Ruseva, Marieta M ^a   Morgan, B Paul ^a   Donev, Rossen M ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; CELL ANTIGEN; NUCLEOLIN; PEPTIDE; PROTEIN KINASE C INHIBITOR; REST68 PEPTIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PHOSPHOPROTEIN; RE1 SILENCING TRANSCRIPTION FACTOR; RE1-SILENCING TRANSCRIPTION FACTOR; REPRESSOR PROTEIN; RNA BINDING PROTEIN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER SUSCEPTIBILITY; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SILENCER ELEMENT; CELL SEPARATION; CYTOTOXICITY; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; IN VITRO STUDY; METABOLISM; METHODOLOGY; NEOPLASM; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD59; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PHOSPHOPROTEINS; REPRESSOR PROTEINS; RNA-BINDING PROTEINS;

EID: 77953448065     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000045     Document Type: Article

References (27)

1. Yan, J., D. J. Allendorf, B. Li, R. Yan, R. Hansen, and R. Donev. 2008. The role of membrane complement regulatory proteins in cancer immunotherapy. Adv. Exp. Med. Biol. 632: 159-174.
2. Walport, M. J. 2001. Complement. First of two parts. N. Engl. J. Med. 344: 1058-1066.
3. Ziller, F., P. Macor, R. Bulla, D. Sblattero, R. Marzari, and F. Tedesco. 2005. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur. J. Immunol. 35: 2175-2183.
4. Macor, P., C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco. 2007. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 67: 10556-10563.
5. Varela, J. C., M. Imai, C. Atkinson, R. Ohta, M. Rapisardo, and S. Tomlinson. 2008. Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res. 68: 6734-6742.
6. Golay, J., M. Lazzari, V. Facchinetti, S. Bernasconi, G. Borleri, T. Barbui, A. Rambaldi, and M. Introna. 2001. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98: 3383-3389.
7. Chen, S. H., T. Caragine, N. K. V. Cheung, and S. Tomlinson. 2000. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res. 60: 3013-3018.
8. Gelderman, K. A., P. J. Kuppen, W. Bruin, G. J. Fleuren, and A. Gorter. 2002. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur. J. Immunol. 32: 128-135.
9. Gelderman, K. A., J. Hakulinen, M. Hagenaars, P. J. Kuppen, S. Meri, and A. Gorter. 2003. Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model. Mol. Immunol. 40: 13-23.
10. Zell, S., N. Geis, R. Rutz, S. Schultz, T. Giese, and M. Kirschfink. 2007. Downregulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin. Exp. Immunol. 150: 576-584.
11. Donev, R. M., L. C. Gray, B. Sivasankar, T. R. Hughes, C. W. van den Berg, and B. P. Morgan. 2008. Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma. Cancer Res. 68: 5979-5987.
12. Tediose, T., M. Kolev, B. Sivasankar, P. Brennan, B. P. Morgan, and R. Donev. 2010. Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation. Nucleic Acids Res. doi:10.1093/nar/gkq013.
13. Belenguer, P., M. Caizergues-Ferrer, J. C. Labbé, M. Dorée, and F. Amalric. 1990. Mitosis-specific phosphorylation of nucleolin by p34cdc2 protein kinase. Mol. Cell. Biol. 10: 3607-3618.
14. Zhou, G., M. L. Seibenhener, and M. W. Wooten. 1997. Nucleolin is a protein kinase C-zeta substrate. Connection between cell surface signaling and nucleus in PC12 cells. J. Biol. Chem. 272: 31130-31137.
15. Le Good, J. A., and D. N. Brindley. 2004. Molecular mechanisms regulating protein kinase Czeta turnover and cellular transformation. Biochem. J. 378: 83-92.
16. Donev, R., R. Horton, S. Beck, T. Doneva, R. Vatcheva, W. R. Bowen, and D. Sheer. 2003. Recruitment of heterogeneous nuclear ribonucleoprotein A1 in vivo to the LMP/TAP region of the major histocompatibility complex. J. Biol. Chem. 278: 5214-5226.
17. Donev, R., A. Newall, J. Thome, and D. Sheer. 2007. A role for SC35 and hnRNPA1 in the determination of amyloid precursor protein isoforms. Mol. Psychiatry 12: 681-690. (Pubitemid 46998252)
18. Kolev, M. V., T. Tediose, B. Sivasankar, C. L. Harris, J. Thome, B. P. Morgan, and R. M. Donev. 2010. Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. Pharmacogenomics J. 10: 12-19.
19. Mujoo, K., D. A. Cheresh, H. M. Yang, and R. A. Reisfeld. 1987. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 47: 1098-1104.
20. Donev, R. M., D. S. Cole, B. Sivasankar, T. R. Hughes, and B. P. Morgan. 2006. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res. 66: 2451-2458.
21. Golubovskaya, V. M., M. Zheng, L. Zhang, J. L. Li, and W. G. Cance. 2009. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer 9: 280.
22. Westbrook, T. F., G. Hu, X. L. L. Ang, P. Mulligan, N. N. Pavlova, A. Liang, Y. M. Leng, R. Maehr, Y. Shi, J. W. Harper, and S. J. Elledge. 2008. SCFbeta- TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452: 370-374.
23. Adams, G. P., and L. M. Weiner. 2005. Monoclonal antibody therapy of cancer, Nat. Biotechnol. 23: 1147-1157.
24. Treon, S., C. Mitsiades, N. Mitsiades, G. Young, D. Doss, R. Schlossman, and K. Anderson. 2001. Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. J. Immunother. (1991) 24: 263-271.
25. Fishelson, Z., N. Donin, S. Zell, S. Schultz, and M. Kirschfink. 2003. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40: 109-123.
26. Mason, J. C., R. Steinberg, E. A. Lidington, A. R. Kinderlerer, M. Ohba, and D. O. Haskard. 2004. Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)- dependent cytoprotective signaling pathway and is inhibited by cyclosporin A. J. Biol. Chem. 279: 41611-41618.
27. Stolz, C., G. Hess, P. S. Hähnel, F. Grabellus, S. Hoffarth, K. W. Schmid, and M. Schuler. 2008. Targeting Bcl-2 family proteins modulates the sensitivity of Bcell lymphoma to rituximab-induced apoptosis. Blood 112: 3312-3321.